Hypertension
Rocheās $310 Million Gamble On Alnylam Pays Off As Hypertension Drug Shows Promise In Phase 2
Anika Sharma
Roche’s recent investment of $310 million into metabolic therapy is yielding positive results, as its collaboration with Alnylam in the ...
FDA Advisors Favor Otsuka’s ReCor and Express Reservations on Medtronic’s Renal Denervation Therapies
Anika Sharma
During a two-day-long FDA meeting, a panel of advisors deliberated over competing proposals for novel renal denervation therapies, ultimately granting ...
Roche & Alnylam partner: Hypertension RNAi Therapy – Zilebesiran
SG Tylor
Source – Roche Roche has recently unveiled an exciting collaboration with Alnylam to jointly develop and commercialize zilebesiran, a promising ...
